218 episódios
- Can GLP-1 medications pay for themselves? We examine a new CVS Health analysis on medical savings and obesity treatment costs.A new CVS Health study suggests that medical savings from reduced hospitalizations and emergency visits could offset the cost of GLP-1 medications for insurers within three years. We break down these findings to see what the data actually proves regarding long-term affordability and why this could shift the conversation around insurance coverage for patients.Beyond the study, we are covering an FDA inspection of Strive Pharmacy regarding sterile compounding practices and environmental monitoring. We also look at new Zepbound discounts for eligible patients and an expansion of the NovoCare support platform. Understanding these pharmaceutical industry developments is essential for navigating access to treatment.Subscribe for weekly obesity medicine news and clinical trial updates, and let us know in the comments: do you think this study will influence how your employer approaches insurance coverage?🔗 **CONNECT WITH ON THE PEN**All our links, community resources, and social platforms: https://linktr.ee/manonthemounjaro📰 News and analysis: https://onthepen.com📺 Subscribe for breaking GLP-1 news, clinical trial updates, pharmaceutical industry developments, and patient advocacy.**SOURCES:**CVS Health GLP-1 Study: https://www.cvshealth.com/content/dam/enterprise/cvs-enterprise/pdfs/2026/GLP1_Whitepaper.pdfFDA Form 483, Strive Pharmacy: https://www.fda.gov/media/196833/downloadNovoCare Announcement: https://www.prnewswire.com/news-releases/novo-launches-the-new-novocare-free-support-program-connects-people-with-wegovy-in-addition-to-home-delivery-everyday-support-wellness-partners-and-rewards-302941304.html*Disclaimer: Dave Knapp is not a medical professional. This content is for informational and educational purposes only and is not medical advice. Observational study findings do not establish causation. FDA Form 483 observations are not final agency determinations of violations.*#GLP1 #Mounjaro #Zepbound #Wegovy #Ozempic #CVSHealth #NovoNordisk #EliLilly #ObesityMedicine #OnThePen
- VOTE FOR DAVE: https://tophost.org/2026/david-knapp
The FDA just issued a NEW eye warning for EVERY GLP-1 medication, including Ozempic, Wegovy, Mounjaro, and Zepbound. But how worried should patients actually be?On today's On The Pen, we're breaking down the FDA's November 9 warning about NAION, a rare condition that can cause sudden vision loss. We'll look at what the data actually show, how rare the risk is, and what patients need to know before making decisions about their medications.PLUS, it's been a massive week in obesity medicine!💊 **Hims & Hers makes a BIG move:** As profit margins shrink and the company shifts toward branded GLP-1s, Hims announces an $8.5 million annual arrangement involving Andrew Huberman and prepares to enter the experimental peptide market.💪 **New tirzepatide research:** A randomized clinical trial shows that resistance training can significantly reduce lean tissue loss while taking Mounjaro or Zepbound.💤 **Foundayo and sleep apnea:** Eli Lilly's oral GLP-1 delivers promising Phase 3 results for patients with obstructive sleep apnea.🔬 **Retatrutide and next-generation medications:** New research on knee osteoarthritis, survodutide's cardiovascular trial, and a quadruple agonist targeting FOUR hormonal pathways.💰 **The GLP-1 affordability crisis:** As pharmaceutical companies report billions in sales, more patients are facing the loss of employer-sponsored coverage.We're talking safety, science, affordability, and what all of this means for REAL patients.**JOIN THE CONVERSATION:** Does the FDA's new eye warning change how you feel about GLP-1 medications? Let me know in the comments!🔗 **FOLLOW ON THE PEN AND FIND ALL OUR LINKS:**https://linktr.ee/manonthemounjaro📰 Latest obesity medicine news:https://onthepen.comThis content is for educational and informational purposes only. I am not a medical professional. Always consult your healthcare provider before making changes to your treatment.#GLP1 #Ozempic #Mounjaro #Zepbound #Wegovy #Retatrutide #WeightLoss #ObesityMedicine #OnThePen - What if the next big breakthrough in obesity medicine isn't a GLP-1 at all?
Novo Nordisk is developing an experimental oral weight-loss medication called LX9851, an ACSL5 inhibitor that targets an entirely different biological pathway than Ozempic, Wegovy, or Zepbound. Novo believes this once-daily pill could potentially deliver 10–15% weight loss without traditional dose titration.
But there's a catch. The drug is still in Phase 1 trials, and those weight-loss projections haven't been demonstrated in humans.
On this week's episode of On The Pen: The Weekly Dose, we're diving into Novo Nordisk's expanding obesity pipeline, the fascinating science behind the ACSL5 enzyme and the intestinal "ileal brake," and why this non-GLP-1 approach could eventually offer new options for patients who struggle with existing treatments.
We'll also examine the preclinical research, its potential alongside semaglutide, and why 2030 or later may be the earliest realistic timeline for this experimental therapy.
Could the future of obesity medicine be bigger than GLP-1s?
💬 Would you consider a weight-loss medication that doesn't directly activate GLP-1 receptors? Let me know in the comments!
🔗 All On The Pen resources, sponsors, and community links: https://linktr.ee/manonthemounjaro
🌐 Latest obesity medicine news: https://onthepen.com
🎙️ On The Pen Live: Monday, Wednesday, and Friday at 11 AM Central.
Subscribe for independent, patient-centered reporting on obesity medicine, GLP-1s, type 2 diabetes, clinical trials, and emerging metabolic therapies.
Disclaimer: LX9851 is investigational and not FDA-approved. Projected weight loss and development timelines are not established clinical outcomes. This content is for educational purposes and is not medical advice. - Retatrutide’s New Phase 3 Data, CagriSema in Menopause, and the Growing GLP‑1 Access CrisisHost Dave Knapp recaps major obesity-drug updates, focusing on Eli Lilly’s triple agonist retatrutide and Novo Nordisk’s CagriSema. He reviews Triumph 1 obesity results (up to 25% average weight loss at 80 weeks) and highlights New England Journal of Medicine Phase 3 data showing large reductions in obstructive sleep apnea events in people with and without type 2 diabetes, while noting uncertainty about weight-loss versus nervous-system mechanisms. He also covers TRANSCEND CKD Phase 2B kidney findings: no significant improvement in measured GFR, but favorable secondary markers including reduced urine albumin in a subset. Novo’s post hoc Redefine 1 analyses show strong CagriSema weight loss across pre-, peri-, and post-menopausal women. He discusses Zealand/Roche’s petrelintide Phase 2 results emphasizing low GI discontinuation and argues tolerability matters as much as potency. The episode closes on worsening affordability and coverage, including employers dropping benefits and Pennsylvania Medicaid GLP-1 spending rising to an estimated $1.3B, warning restricted access fuels the gray market.00:00 Big Week in Obesity Drugs00:53 Show Intro and Disclaimers02:03 Sponsor Spotlight VoaFit03:06 Retatrutide Weight Loss Context05:27 Sleep Apnea Phase 3 Results10:23 Beyond Weight Loss Benefits12:14 Kidney Study Nuance16:53 CagriSema Menopause Data19:20 Petrelintide Amylin Update23:33 Top Host Voting Pitch ( otplinks.com )25:29 Access and Coverage Crisis27:42 Medicaid Costs and Gray Market31:21 Wrap Up and Schedule
- Specific lots of compounded tirzepatide have been recalled over sterility concerns, another pharmacy recently recalled compounded semaglutide after particulate matter was identified, patients have reported visible strands and fibers in other compounded GLP-1 vials, and now FDA inspectors have documented black mold, insects, hidden paperwork, and questionable testing practices at facilities manufacturing GLP-1 active ingredients.So, should people taking compounded GLP-1s panic? No.Millions of people have used compounded semaglutide and tirzepatide, and these incidents still appear relatively uncommon compared with the enormous scale of use. But patients deserve transparency about who made their medication, where the active ingredient came from, what testing was performed, and what happens when something goes wrong.In this episode of On The Pen, we break down:- The Apothecary Pharma compounded tirzepatide recall- The affected lots and sterility concerns- Apollo Care and the compounded semaglutide “floaters”- The Hyalo/NewLife vials with reported visible strands or particulate- FDA findings involving black mold, insects, records, and GLP-1 API suppliers in China- Why these stories should not become Pharma vs. compounding- Why pharmaceutical manufacturers deserve scrutiny too- CagriSema, amylin, and why I’m watching January 2027- Lilly’s $1.1 billion METiS TechBio deal- Why the future of obesity and diabetes treatment needs to move beyond GLP-1s and weekly shots foreverAffected lot numbers and supporting links:👉 https://otplinks.comThe goal here is not fear. It is giving patients enough information to understand what they are actually injecting and enough context to put these stories into perspective.Subscribe to On The Pen for breaking GLP-1, obesity, diabetes, and metabolic health news.🔗 All my links: https://linktr.ee/manonthemounjaro#GLP1 #Tirzepatide #Semaglutide #Mounjaro #Zepbound #Ozempic #Wegovy #CompoundedGLP1 #CagriSema #WeightLossNews
Mais podcasts de Medicina
Podcasts em tendência em Medicina
Sobre On The Pen GLP-1 News
On The Pen is the leading GLP-1 news podcast and platform covering obesity medicine, FDA actions, drug shortages, access policy, and the business of NuSH therapies. The podcast is in the top 0.5% of all podcasts globally, and On The Pen is a top Substack best-seller.
Sítio Web de podcastOuve On The Pen GLP-1 News, Behind The Knife: The Surgery Podcast e muitos outros podcasts de todo o mundo com a aplicação radio.pt

Obtenha a aplicação gratuita radio.pt
- Guardar rádios e podcasts favoritos
- Transmissão via Wi-Fi ou Bluetooth
- Carplay & Android Audo compatìvel
- E ainda mais funções
On The Pen GLP-1 News: Podcast do grupo















